|
Vol. 4 • Issue 4 • Page 27
1 http://www.nytimes.com/2008/07/15/health/15well.html?_r=1
2 http://www.boston.com/business/healthcare/articles/2008/01/07/fda_studies_pain_in_osteoperosis_drugs/
3 http://www.washingtonpost.com/wp-dyn/content/article/2008/10/27/AR2008102700763.html
4 Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005 Jul; 87(7):1609-18.
5 Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov 15;357(20):2028-39.
6 McClung MR et al. Denosumab in postmenopausal women with low bone mineral density. AMG 162 Bone Loss Study Group. N Engl J Med. 2006 Feb 23;354(8):821-31.
7 Maclean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp 1 M, et al. Systematic review-comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213.
8 Black, D. M et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. HORIZON Pivotal Fracture Trial (2007). NEJM 356: 1809-1822
9 Shanbhag AS. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg. 2006 Apr;14(4):215-25.
10 Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-51.
11 Lyles KW et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. HORIZON Recurrent Fracture Trial. N Engl J Med. 2007;357:nihpa40967.
12 Grewal VS, Fayans EP. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management. Todays FDA. 2008 Aug;20(8):38-41, 43-6.
13 Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med. 2008 Sep 25;359(13):1410-1.
14 Belhadjali H, Slim R, Aouam K, Youssef M, Zili J. Cutaneous vasculitis induced by risedronate. Allergy. 2008 Oct;63(10):1405.
15 FDA Alert 1/7/2008. "Information on Bisphosphonates." http://www.fda.gov/cder/drug/infopage/bisphosphonates/default.htm
16 Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation [letter]. N Engl J Med 2007;356:1895-6.
17 FDA. November 12, 2008 - Update to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates http://www.fda.gov/cder/drug/early_comm/bisphosphonates_update_200811.htm
18 Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., Psaty, B. M. (2008). Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med 168: 826-831
19 Sorensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D, Cummings, S. R, Baron, J. A (2008). Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336: 813-816
20 ACCP annual meeting proceedings. http://www.chestnet.org/about/press/releases/2008/CHEST/PDF/OsteoporosisAtrialFib.pdf
21 Majumdar, S. R (2008). Oral bisphosphonates and atrial fibrillation. BMJ 336: 784-785
22 Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007 Mar;89(3):349-53.
23 Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008 May-Jun;22(5):346-50.
24 Sayed-Noor AS, Sjödén GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report. Acta Orthop. 2008 Aug;79(4):565-7.
25 Fleisch H: Can bisphosphonates be given to patients with fractures? J Bone Miner Res 2001;16:437-440.
26 Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA: Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996;14:74-79.
|